Andrew Tingey

Recently featured in the “IAM300” list of the world’s leading IP strategists, Dr Andrew Tingey has over 20 years experience in a variety of commercial roles centred around licensing and other IP-based transactions, having negotiated a number of high value deals in multiple sectors, including the out-licence of novel gene therapy technologies from the UK’s Gene Therapy Consortium to Boehringer Ingelheim in 2018.

Prior to joining IP Pragmatics, Andrew was Senior Director, Licensing & IP Strategy at Eagle Genomics, a Board Director at Imperial Innovations Ltd., the company that successfully commercialised hundreds of technologies from Imperial College London and Director of Licensing at Royal DSM NV, where he led the DSM corporate licensing team based near Maastricht, the Netherlands.

Andrew has held Certified Licensing Professional accreditation since 2012 and also holds a PhD in biochemistry from the University of Leicester, a BSc in biochemistry from the University of York and an MBA from The Open University Business School in the United Kingdom.

View Team Next